Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Turner (Aberdeen (Aberdeenshire), United Kingdom). Asthma treatment in step 3: the cases for adding LABA or doubling ICS. Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?

Member's Comments

No comment yet.

Related content which might interest you: Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004 Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence? Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2-agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011 Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Is the combination of long-acting β2-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma? Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003 Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003 Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Asthma control and lung function after step down from high dose ICS/LABA combination therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011